BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 16259581)

  • 1. Review of immediate-release omeprazole for the treatment of gastric acid-related disorders.
    Castell D
    Expert Opin Pharmacother; 2005 Nov; 6(14):2501-10. PubMed ID: 16259581
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of the effects of immediate-release omeprazole powder for oral suspension and pantoprazole delayed-release tablets on nocturnal acid breakthrough in patients with symptomatic gastro-oesophageal reflux disease.
    Castell D; Bagin R; Goldlust B; Major J; Hepburn B
    Aliment Pharmacol Ther; 2005 Jun; 21(12):1467-74. PubMed ID: 15948814
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of the effects of immediate-release omeprazole oral suspension, delayed-release lansoprazole capsules and delayed-release esomeprazole capsules on nocturnal gastric acidity after bedtime dosing in patients with night-time GERD symptoms.
    Katz PO; Koch FK; Ballard ED; Bagin RG; Gautille TC; Checani GC; Hogan DL; Pratha VS
    Aliment Pharmacol Ther; 2007 Jan; 25(2):197-205. PubMed ID: 17229243
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Omeprazole/Antacid-powder suspension-Santarus: omeprazole/sodium bicarbonate powder-Santarus, SAN 05.
    Drugs R D; 2004; 5(6):349-50. PubMed ID: 15563239
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Review article: immediate-release proton-pump inhibitor therapy--potential advantages.
    Howden CW
    Aliment Pharmacol Ther; 2005 Dec; 22 Suppl 3():25-30. PubMed ID: 16303034
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Control of 24-hour intragastric acidity with morning dosing of immediate-release and delayed-release proton pump inhibitors in patients with GERD.
    Howden CW; Ballard ED; Koch FK; Gautille TC; Bagin RG
    J Clin Gastroenterol; 2009 Apr; 43(4):323-6. PubMed ID: 18758373
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Esomeprazole: a review of its use in the management of acid-related disorders in the US.
    Scott LJ; Dunn CJ; Mallarkey G; Sharpe M
    Drugs; 2002; 62(7):1091-118. PubMed ID: 11985491
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gastric acidity and acid breakthrough with twice-daily omeprazole or lansoprazole.
    Katz PO; Hatlebakk JG; Castell DO
    Aliment Pharmacol Ther; 2000 Jun; 14(6):709-14. PubMed ID: 10848653
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Acid control and regression of Barrett's esophagus: is the glass half full or half empty?
    Castell DO; Katz PO
    Am J Gastroenterol; 1997 Dec; 92(12):2329-30. PubMed ID: 9399786
    [No Abstract]   [Full Text] [Related]  

  • 10. An evaluation of the clinical implications of acid breakthrough in patients on proton pump inhibitor therapy.
    Nzeako UC; Murray JA
    Aliment Pharmacol Ther; 2002 Jul; 16(7):1309-16. PubMed ID: 12144581
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Omeprazole/antacid-powder suspension--Santarus: Acitrel, Rapinex Powder for oral suspension, SAN 05.
    Drugs R D; 2004; 5(4):234-5. PubMed ID: 15230632
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A review of omeprazole use in the treatment of acid-related disorders in children.
    Zimmermann AE; Walters JK; Katona BG; Souney PE; Levine D
    Clin Ther; 2001 May; 23(5):660-79; discussion 645. PubMed ID: 11394727
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The basis for the decreased response to proton pump inhibitors in gastro-oesophageal reflux disease patients without erosive oesophagitis.
    Gardner JD; Gallo-Torres H; Sloan S; Robinson M; Miner PB
    Aliment Pharmacol Ther; 2003 Nov; 18(9):891-905. PubMed ID: 14616153
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rabeprazole: a review of its use in acid-related gastrointestinal disorders.
    Langtry HD; Markham A
    Drugs; 1999 Oct; 58(4):725-42. PubMed ID: 10551440
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Control of nocturnal gastric acidity: a role for low dose bedtime ranitidine to supplement daily omeprazole.
    Robinson M; Rodriguez-Stanley S; Ciociola AA; Filinto J; Zubaidi S; Miner PB; Gardner JD
    Dig Dis Sci; 2002 Feb; 47(2):265-73. PubMed ID: 11855540
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The clinical importance of proton pump inhibitor pharmacokinetics.
    Yacyshyn BR; Thomson AB
    Digestion; 2002; 66(2):67-78. PubMed ID: 12428065
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bedtime H2 blockers improve nocturnal gastric acid control in GERD patients on proton pump inhibitors.
    Xue S; Katz PO; Banerjee P; Tutuian R; Castell DO
    Aliment Pharmacol Ther; 2001 Sep; 15(9):1351-6. PubMed ID: 11552905
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Esomeprazole: a review of its use in the management of acid-related disorders.
    Scott LJ; Dunn CJ; Mallarkey G; Sharpe M
    Drugs; 2002; 62(10):1503-38. PubMed ID: 12093317
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Review article: putting immediate-release proton-pump inhibitors into clinical practice--improving nocturnal acid control and avoiding the possible complications of excessive acid exposure.
    Katz PO
    Aliment Pharmacol Ther; 2005 Dec; 22 Suppl 3():31-8. PubMed ID: 16303035
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nocturnal acid breakthrough: clinical significance and correlation with esophageal acid exposure.
    Ours TM; Fackler WK; Richter JE; Vaezi MF
    Am J Gastroenterol; 2003 Mar; 98(3):545-50. PubMed ID: 12650785
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.